Loading...
Market
AstraZeneca's response strategy to China fraud investigation fallout by Q1 2025?
2
Resolution / Starting Odds
Restructuring of Chinese operations • 25%
Increased compliance measures • 25%
Leadership changes • 25%
No significant changes • 25%
Official statements or press releases from AstraZeneca
Story
AstraZeneca Faces Investigation in China Over Insurance Fraud Involving Tagrisso and Leon Wang
Nov 5, 2024, 10:00 AM
AstraZeneca is under investigation in China, with high-ranking executive Leon Wang and other personnel being scrutinized by authorities. The investigation stems from allegations that AstraZeneca China's sales team falsified genetic test results to ensure state-backed insurance would cover the company's lung cancer drug, Tagrisso. This insurance fraud has reportedly involved dozens of senior executives within the company and has led to prosecutions, as reported by Caixin Global. AstraZeneca's Chinese market, which accounts for approximately 13% of its $5.8 billion in revenue, is now facing significant challenges due to these allegations. Wang Lei, the executive vice president overseeing AstraZeneca’s operations in China, is cooperating with the authorities, though the details of the investigation remain unclear.
View original story
Similar markets
Increase investment in China • 25%
Reduce operations in China • 25%
No change in strategy • 25%
Other strategic response • 25%
Yes • 50%
No • 50%
Public apology and reform announcement • 25%
Focus on new business initiatives • 25%
Legal defense and appeal • 25%
No public response • 25%
Increase investments in compliance • 25%
Launch new competitive strategies • 25%
No major changes • 25%
Other • 25%
Strengthen compliance measures • 25%
Increase diplomatic engagement • 25%
No significant changes • 25%
Other strategic changes • 25%
Public apology • 25%
Denial of wrongdoing • 25%
Commitment to improve transparency • 25%
No comment • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 5-10% • 25%
Stock price remains within +/- 5% • 25%
Stock price decreases by more than 5% • 25%
New regulations • 25%
Public apology • 25%
Fines to companies • 25%
No significant action • 25%
No wrongdoing found • 25%
Minor violations found • 25%
Major violations found • 25%
Undetermined outcome • 25%
No response • 25%
Denial of contamination claims • 25%
Acknowledgement of contamination and corrective measures • 25%
Legal action against claimants • 25%
Increase lobbying efforts • 25%
Enhance compliance measures • 25%
Shift focus away from China • 25%
Other strategic actions • 25%